Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accumulated Depreciation: 2015-2024

Historic Accumulated Depreciation for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $419,000.

  • Syndax Pharmaceuticals' Accumulated Depreciation rose 1.95% to $419,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $419,000, marking a year-over-year increase of 1.95%. This contributed to the annual value of $419,000 for FY2024, which is 1.95% up from last year.
  • According to the latest figures from FY2024, Syndax Pharmaceuticals' Accumulated Depreciation is $419,000, which was up 1.95% from $411,000 recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Accumulated Depreciation registered a high of $443,000 during FY2021, and its lowest value of $399,000 during FY2020.
  • For the 3-year period, Syndax Pharmaceuticals' Accumulated Depreciation averaged around $409,667, with its median value being $411,000 (2023).
  • In the last 5 years, Syndax Pharmaceuticals' Accumulated Depreciation grew by 28.71% in 2020 and then declined by 9.93% in 2022.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Accumulated Depreciation stood at $399,000 in 2020, then grew by 11.03% to $443,000 in 2021, then decreased by 9.93% to $399,000 in 2022, then increased by 3.01% to $411,000 in 2023, then grew by 1.95% to $419,000 in 2024.